AU2009306424A1 - Ligands that have binding specificity for DC-SIGN - Google Patents

Ligands that have binding specificity for DC-SIGN Download PDF

Info

Publication number
AU2009306424A1
AU2009306424A1 AU2009306424A AU2009306424A AU2009306424A1 AU 2009306424 A1 AU2009306424 A1 AU 2009306424A1 AU 2009306424 A AU2009306424 A AU 2009306424A AU 2009306424 A AU2009306424 A AU 2009306424A AU 2009306424 A1 AU2009306424 A1 AU 2009306424A1
Authority
AU
Australia
Prior art keywords
lip1
seq
amino acid
sign
lipi
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2009306424A
Other languages
English (en)
Inventor
Rudolf Maria De Wildt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Domantis Ltd
Original Assignee
Domantis Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Domantis Ltd filed Critical Domantis Ltd
Publication of AU2009306424A1 publication Critical patent/AU2009306424A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
AU2009306424A 2008-10-21 2009-10-19 Ligands that have binding specificity for DC-SIGN Abandoned AU2009306424A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10708508P 2008-10-21 2008-10-21
US61/107,085 2008-10-21
PCT/EP2009/063655 WO2010046337A2 (en) 2008-10-21 2009-10-19 Ligands that have binding specificity for dc-sign

Publications (1)

Publication Number Publication Date
AU2009306424A1 true AU2009306424A1 (en) 2010-04-29

Family

ID=42062429

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2009306424A Abandoned AU2009306424A1 (en) 2008-10-21 2009-10-19 Ligands that have binding specificity for DC-SIGN

Country Status (16)

Country Link
US (1) US20110257373A1 (https=)
EP (1) EP2356149A2 (https=)
JP (1) JP2012506237A (https=)
KR (1) KR20110071139A (https=)
CN (1) CN102257009A (https=)
AR (1) AR073905A1 (https=)
AU (1) AU2009306424A1 (https=)
BR (1) BRPI0919714A2 (https=)
CA (1) CA2740856A1 (https=)
EA (1) EA201100488A1 (https=)
IL (1) IL212086A0 (https=)
MX (1) MX2011004244A (https=)
TW (1) TW201019962A (https=)
UY (1) UY32189A (https=)
WO (1) WO2010046337A2 (https=)
ZA (1) ZA201102763B (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010046338A1 (en) * 2008-10-21 2010-04-29 Domantis Limited Composition for targeting dendritic cells
WO2013095973A1 (en) * 2011-12-19 2013-06-27 The Rockefeller University Hdc-sign binding peptides
WO2023028593A2 (en) * 2021-08-27 2023-03-02 University Of Georgia Research Foundation, Inc. Targeted nanoparticles and their uses related to infectious disease
CN118184795B (zh) * 2022-12-13 2025-03-21 成都维瑾柏鳌生物医药科技有限公司 抗hiv-1的重组蛋白及其应用
CN120591214A (zh) * 2025-07-02 2025-09-05 山东第一医科大学第二附属医院 一种过表达dc-sign基因的重组arh77细胞系及其构建方法与应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0598108A1 (en) * 1992-06-05 1994-05-25 Dade Produktions AG Rabbit single domain antibody and use thereof
CA2505316C (en) * 2002-11-08 2014-08-05 Ablynx N.V. Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
EP1587838B1 (en) * 2003-01-10 2015-04-15 Ablynx N.V. Therapeutic polypeptides, homologues thereof, fragments thereof and their use in modulating platelet-mediated aggregation
US20090005257A1 (en) * 2003-05-14 2009-01-01 Jespers Laurent S Process for Recovering Polypeptides that Unfold Reversibly from a Polypeptide Repertoire
CN1845938B (zh) * 2003-06-30 2010-05-26 杜门蒂斯有限公司 多肽
DE602004025711D1 (de) * 2003-08-21 2010-04-08 Lipotek Pty Ltd In vivo targeting von dendritischen zellen
EA012622B1 (ru) * 2004-06-01 2009-10-30 Домэнтис Лимитед Биспецифичные гибридные антитела с увеличенным периодом полувыведения из сыворотки
CA2588892A1 (en) * 2004-12-02 2006-06-08 Dormantis Limited Anti-il-1r1 single domain antibodies and therapeutic uses
CA2589800A1 (en) * 2004-12-02 2006-06-08 Domantis Limited Bispecific domain antibodies targeting serum albumin and glp-1 or pyy
CA2601115A1 (en) * 2005-03-18 2006-09-21 Domantis Limited Antibodies against candida antigens
US20100021473A1 (en) * 2005-12-06 2010-01-28 Domantis Limited Bispecific Ligands With Binding Specificity to Cell Surface Targets and Methods of Use Therefor
JP2009518024A (ja) * 2005-12-06 2009-05-07 ドマンティス リミテッド Ｅｇｆｒおよび／またはｖｅｇｆに対して結合特異性を有するリガンドおよびその使用法
JP2009523460A (ja) * 2006-01-24 2009-06-25 ドマンティス リミテッド Ｉｌ−４および／またはｉｌ−１３に結合するリガンド
AU2007300543A1 (en) * 2006-09-26 2008-04-03 Alexion Pharmaceuticals, Inc. Compositions and methods for enhancing an adjuvant
WO2008070363A2 (en) * 2006-10-31 2008-06-12 Domantis Limited Intrabodies
CN101182539A (zh) * 2007-11-06 2008-05-21 浙江大学 Dc-sign启动子荧光素酶报告质粒的构建方法

Also Published As

Publication number Publication date
WO2010046337A2 (en) 2010-04-29
BRPI0919714A2 (pt) 2015-12-08
AR073905A1 (es) 2010-12-09
TW201019962A (en) 2010-06-01
KR20110071139A (ko) 2011-06-28
WO2010046337A3 (en) 2010-07-01
US20110257373A1 (en) 2011-10-20
IL212086A0 (en) 2011-06-30
CA2740856A1 (en) 2010-04-29
JP2012506237A (ja) 2012-03-15
UY32189A (es) 2010-05-31
EP2356149A2 (en) 2011-08-17
CN102257009A (zh) 2011-11-23
ZA201102763B (en) 2012-09-26
EA201100488A1 (ru) 2011-12-30
MX2011004244A (es) 2011-05-25

Similar Documents

Publication Publication Date Title
JP7019198B2 (ja) 補体関連疾患の予防及び治療のためのｃ５抗体及び方法
AU2025271449A1 (en) Bispecific Antibody Constructs Binding DLL3 And CD3
KR101791372B1 (ko) Ｃｄ２８ 결합에 대해 １가인 조성물 및 사용 방법
ES2263984T3 (es) Ligandos doble-especificos con una vida media serica aumentada.
AU2019201141B2 (en) Novel antibody binding to TFPI and composition comprising the same
US20130230540A1 (en) Compositions monovalent for cd28 binding and methods of use
CN105121467A (zh) 抗cd47抗体及其使用方法
WO2015085847A1 (zh) Pd-1抗体、其抗原结合片段及其医药用途
RS61493B1 (sr) Konstrukti multispecifičnih antitela
CN102686239B (zh) 稳定的抗-tnfr1多肽、抗体可变结构域和拮抗剂
EP3922647A1 (en) Anti-pd-1 antibody, antigen-binding fragment thereof and pharmaceutical use thereof
EP2453920A2 (en) Antagonists, uses & methods for partially inhibiting tnfr1
US9028817B2 (en) Stable anti-TNFR1 polypeptides, antibody variable domains and antagonists
WO2022199590A1 (zh) 一种靶向bcma的纳米抗体及其应用
CN114805561B (zh) 针对呼吸道合胞病毒的蛋白结合分子
CN116284377A (zh) 抗人血管生成素3纳米抗体及其应用
US20110257373A1 (en) Ligands that have binding specificity for dc-sign
CN110114370A (zh) 能够与人白细胞介素-6受体结合的抗体或其抗原结合片段
CN114269788B (zh) 一种能够与人4-1bb结合的分子及其应用
RU2794359C2 (ru) Полипептиды, которые связываются с компонентом комплемента c5 или сывороточным альбумином, и их белки слияния
HK40123789A (zh) 优化的抗tl1a抗体
HK40042163B (zh) 优化的抗tl1a抗体
HK40012919B (zh) 能够与人白细胞介素-6受体结合的抗体或其抗原结合片段

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period